Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 30, 2015 8:51 AM ET

Healthcare Equipment and Supplies

Company Overview of Immucor, Inc.

Company Overview

Immucor Inc. and its subsidiaries develop, manufacture, and sell reagents and automated systems used primarily by hospitals, clinical labs, and blood banks in tests to detect and identify certain properties of the cell and serum components of human blood before blood transfusions. The company’s reagent product lines include abo blood grouping and Rh blood typing reagents, anti-human globulin serums, reagent red blood cells, rare serums, antibody potentiators, quality control systems, monoclonal antibody-based reagents, technical proficiency systems, and a fetal bleed screen kit, as well as Capture-P, Capture-R, Capture-CMV, Capture-S, and Capture-R Select reagents. These are used in tests to...

3130 Gateway Drive

PO Box 5625

Norcross, GA 30091

United States

Founded in 1982

1,090 Employees





Key Executives for Immucor, Inc.

Chief Executive Officer, President, Director and Member of Compensation Committee
Age: 60
Chief Financial Officer, Chief Accounting Officer and Vice President
Age: 52
Vice President of Operations
Vice President of International Finance
Age: 57
Compensation as of Fiscal Year 2014.

Immucor, Inc. Key Developments

Immucor, Inc., Q3 2015 Fixed Income Call, May 06, 2015

Immucor, Inc., Q3 2015 Fixed Income Call, May 06, 2015

Immucor, Inc. Announces Consolidated Earnings Results for the Second Quarter of Fiscal Year 2015; Provides Earnings Guidance the Second Half and Full Fiscal Year 2015

Immucor, Inc. announced consolidated earnings results for the second quarter of fiscal year 2015. For the quarter, revenue was $96.3 million, a decrease of 3.9% on a GAAP basis when compared with prior quarter. On a like-for-like basis, revenue increased 2% over the prior year quarter. The like-for-like comparison is adjusted for FX, as well as for additional ship cycles in the prior year quarter. Adjusted EBITDA was $33.4 million compared with $38.5 million in the prior year quarter. This decrease of 13.2% was due to the reduced gross margin and increased operating expenses as previously discussed. Total net debt was $1,039,800,000 at the end of the quarter, down $1 million on a sequential quarterly basis. The company expects an acceleration in the company’s financial performance in the second half of the year and expects to generate top and bottom line growth on a full year basis for fiscal year 2015.

Immucor, Inc., Q2 2015 Fixed Income Call, Jan 22, 2015

Immucor, Inc., Q2 2015 Fixed Income Call, Jan 22, 2015

Similar Private Companies By Industry

Company Name Region
Draeger Medical, Inc. United States
Hatch Medical, L.L.C. United States
Ionix Medical, Inc. United States
Nipro Medical Corporation United States
Singulex, Inc. United States

Recent Private Companies Transactions

October 1, 2014
Sentilus, Inc.
June 2, 2014
Organ-i, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Immucor, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at